Coiled Therapeutics Company Description

Coiled Therapeutics plc, a clinical-stage oncology company, develops and commercialises clinical-stage oncology therapeutics in the United Kingdom and internationally.

The company’s lead asset is AO-252, a first-in-class, small molecule inhibitor of TACC3, currently in a Phase I clinical trial for advanced solid tumours, including ovarian and prostate cancer.

The company also offers a STAT-6 siRNA programme targeting immunology indications such as asthma, fibrosis, eczema, and allergic disease, with plans for assessment towards Phase I clinical trials.

The company is based in London, United Kingdom.

Coiled Therapeutics plc

Country	United Kingdom
Industry	Unit Investment Trusts, Face-Amount Certificate Offices, and Closed-End Management Investment Offices
Employees	7
CEO	Sridhar Vempati

Contact Details

Address: 167-169 Great Portland Street London, W1W 5PF United Kingdom
Phone	44 20 3918 8633
Website	coiledplc.com

Stock Details

Ticker Symbol	COIL
Exchange	London Stock Exchange AIM
Reporting Currency	GBP
SIC Code	6726

Key Executives

Name	Position
Sridhar Vempati	Chief Executive Officer